<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04985214</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/19/0465</org_study_id>
    <nct_id>NCT04985214</nct_id>
  </id_info>
  <brief_title>Assessment of the Quality of Life of Patients With Lymphomas Treated With Oral Therapy</brief_title>
  <acronym>EVEREST</acronym>
  <official_title>Assessment of the Quality of Life of Patients With Lymphomas Treated With Oral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The emergence of new anti-cancer drugs orally administered has revolutionized the prognosis&#xD;
      and modalities of management of several lymphomas over the past decade. Today, half of&#xD;
      patients receive oral therapy at home. Ibrutinib, acalabrutinib, idelalisib, venetoclax and&#xD;
      lenalidomide are oral therapies used in the treatment of Chronic Lymphoid Leukemia,&#xD;
      Follicular Lymphoma, Waldenström's disease and mantle cell lymphoma, in relapsing but soon to&#xD;
      be 1st line.&#xD;
&#xD;
      Nevertheless, clinical trials leading to marketing authorizations for these drugs were&#xD;
      performed in a small number of patients and very little data is available on their use in&#xD;
      real life conditions. Their impact on the quality of life of patients also remains to be&#xD;
      assessed.&#xD;
&#xD;
      The aim of this clinical research is to evaluate quality of life of patients at the&#xD;
      initiation of the first oral therapy and every year for 5 years. This study will also&#xD;
      identify factors (biological and non-biological: quality of life, shared decision-making ...)&#xD;
      associated with a good response of patients and follow-up for the occurrence of long-term&#xD;
      adverse reactions (5 years).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective longitudinal cohort. This observational study is monocentric. For each patient,&#xD;
      data will be collected during 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 14, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of life measurement</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluation of the quality of life score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of patients factors</measure>
    <time_frame>5 years</time_frame>
    <description>Collect of clinical and socio-professional characteristics of the patient</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">310</enrollment>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>Oral therapy</arm_group_label>
    <description>Patients included in the PK-E3i clinical study or patients with hemopathies starting treatment with oral therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <description>Questionnaire on the quality of life</description>
    <arm_group_label>Oral therapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with hemopathies and starting treatment with oral therapy (idelalisib, ibrutinib,&#xD;
        venetoclax, lenalidomide, acalabrutinib…)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients included in the PK-E3i clinical study OR&#xD;
&#xD;
          -  Over the age of 18&#xD;
&#xD;
          -  Patients with hemopathies and starting treatment with oral therapy (idelalisib,&#xD;
             ibrutinib, venetoclax, lenalidomide, acalabrutinib…)&#xD;
&#xD;
          -  Be able to understand the objective and the constraints related to research&#xD;
&#xD;
          -  Patient having read the information notice and the non-objection form&#xD;
&#xD;
          -  Social Security affiliation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Persons under legal protection of adults&#xD;
&#xD;
          -  Patients under judicial protection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Loïc YSEBAERT, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Loïc YSEBAERT, Prof.</last_name>
    <phone>0531156351</phone>
    <phone_ext>33</phone_ext>
    <email>ysebaert.loic@iuct-oncopole.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fabien DESPAS, MD</last_name>
    <email>fabien.despas@univ-tlse3.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Loïc YSEBAERT</name>
      <address>
        <city>Toulouse 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loïc YSEBAERT, Prof.</last_name>
      <phone>0531156351</phone>
      <email>ysebaert.loic@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 26, 2021</study_first_submitted>
  <study_first_submitted_qc>July 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2021</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oral therapy</keyword>
  <keyword>lymphoma</keyword>
  <keyword>quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

